Work

Supplementary Figure from Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Figure from Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC

DOI: 10.1158/1078-0432.22486431.v1

Authors: Julia Foldi, Adriana Kahn, Andrea Silber, Tao Qing, Emily Reisenbichler, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Anees Chagpar, Tristen Park, Adam Blanchard, Kim Blenman, David L. Rimm, Lajos Pusztai

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361812567

Cites:

Cited by:

Related to: 10